Immunostimulatory oligodeoxynucleotides
AssigneeValneva Austria GmbH
InventorsWalter Schmidt, Karen Lingnau, Carola Schellack, Alena Egyed
Life of this patent
Estimating the term…
Loading patent…
AssigneeValneva Austria GmbH
InventorsWalter Schmidt, Karen Lingnau, Carola Schellack, Alena Egyed
Estimating the term…
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) 1 wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, de-oxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-,deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-,deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxy-guanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
Use of an oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I)
Dependencies are inferred from the claim text.